A phase III clinical study to compare the combination therapy of eribulin mesylate + trastuzumab + pertuzumab with paclitaxel or Docetaxel + trastuzumab + pertuzumab - JBCRG-M06 (EMERALD)

Japan Breast Cancer Research Group0 个研究点目标入组 446 人开始时间: 2017年6月28日最近更新: 2023年10月17日

试验速览

暂无简介。

•1)Patients planning to undergo radical surgery if they respond to a treatment 2)Patients who have non-hematological adverse events assessed as Grade >=3 in the Common Terminology Criteria for Adverse Events ver. 4.0 in the Japanese JCOG version (CTCAE v4.0-JCOG) at the time of enrollment 3)Patients who have symptomatic metastases to the central nervous system or whose symptoms are hard to control 4)Patients who have active double cancer 5)Patients who have poorly controlled hypertension, or unstable angina 6)Patients who have a past history of congestive heart failure assessed as Class ll or higher in the New York Heart Association (NYHA) classification, or clinically significant arrhythmia requiring treatment 7)Patients with a past history of myocardial infarction within 6 months before enrollment 8)Patients who are expected to undergo major surgical treatment or who had severe injury within 28 days before enrollment, or who require major surgical treatment during the study treatment period 9)Patients with interstitial pneumonia which is symptomatic or requires treatment 10)Pregnant women, those with a positive pregnancy test, and lactating women 11)Patients with active systemic infection (including HCV and HBV), or who are found to be HIV-positive 12)Patients with hypersensitivity against pertuzumab and trastuzumab 13)Patients whom the investigator consider unable or unwilling to follow the protocol requirements

发起方